We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
+$145M
Cap. Flow %
8.42%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Miscellaneous 81.15%
2 Healthcare 18.37%
3 Financials 0.23%
4 Technology 0.2%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
251
PUT
DELISTED
Zogenix, Inc.
ZGNX
$165K 0.01%
+136
New +$1.49K
SLS icon
252
PUT
SELLAS Life Sciences
SLS
$2.28B
$164K 0.01%
+1
New +$5.82K
OTIC
253
DELISTED
Otonomy, Inc.
OTIC
$159K 0.01%
+10,000
New +$167K
ONSIW
254
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$154K 0.01%
930,592
+28,542
+3% +$9.06K
SLNO
255
DELISTED
Soleno Therapeutics
SLNO
$145K 0.01%
2,387
-889
-27% -$61.6K
TXMD icon
256
TherapeuticsMD
TXMD
$25M
$144K 0.01%
499
-182
-27% -$56.4K
PARN
257
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$138K 0.01%
200,549
-169,151
-46% -$201K
IOVA icon
258
CALL
Iovance Biotherapeutics
IOVA
$4.24B
$136K 0.01%
195
-301
-61% -$2.07K
NKTR icon
259
CALL
Nektar Therapeutics
NKTR
$2.28B
$135K 0.01%
+7
New +$1.42K
NURO
260
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$123K 0.01%
260
-83
-24% -$62K
CEMP
261
DELISTED
Cempra, Inc.
CEMP
$121K 0.01%
+43,121
New +$523K
AKTX
262
Akari Therapeutics
AKTX
$20M
$120K 0.01%
22
– –
RNVAZ
263
DELISTED
Rennova Health, Inc. Warrant
RNVAZ
$118K 0.01%
4,926,013
+1,243,999
+34% +$48.6K
ARCT icon
264
PUT
Arcturus Therapeutics
ARCT
$450M
$117K 0.01%
80
– –
FOCL
265
PUT
EDAP TMS S.A.
FOCL
$187M
$112K 0.01%
341
+159
+87% +$473
DVAX
266
PUT
DELISTED
Dynavax Technologies
DVAX
$102K 0.01%
258
-7,370
-97% -$54K
VYNT
267
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$97K 0.01%
480
-247
-34% -$56.2K
AST
268
CALL
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$92K 0.01%
200
– –
ALPN
269
DELISTED
Alpine Immune Sciences Inc
ALPN
$90K 0.01%
10,001
-56,912
-85% -$1.13M
CLRBW
270
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$85K ﹤0.01%
201,889
-26,899
-12% -$6.06K
ZSAN
271
DELISTED
Zosano Pharma Corporation
ZSAN
$81K ﹤0.01%
148
– –
ACUR
272
DELISTED
Acura Pharmaceuticals
ACUR
$79K ﹤0.01%
103,444
-249,391
-71% -$261K
FOCL
273
EDAP TMS S.A.
FOCL
$187M
$76K ﹤0.01%
22,993
-522,925
-96% -$1.55M
ADXS
274
DELISTED
Advaxis Inc
ADXS
$75K ﹤0.01%
+696
New +$93.9K
TPST icon
275
Tempest Therapeutics
TPST
$12.5M
$74K ﹤0.01%
17
– –
9 10
11
12 13

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management deployed $145M of net new capital in Q4 2016, opening 67 new positions and adding to 88 existing holdings. Its largest new stake was Eli Lilly: 213,113 shares worth $15.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 81% of assets, down from 90% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Regenxbio, an estimated $4.1M trimmed.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.